Constipation News and Research

Latest Constipation News and Research

Kanuma approved as first treatment for patients with LAL deficiency

Today, the U.S. Food and Drug Administration approved Kanuma (sebelipase alfa) as the first treatment for patients with a rare disease known as lysosomal acid lipase (LAL) deficiency.

8 Dec 2015

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda Pharmaceutical Company Limited today announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), showing that treatment with NINLARO (ixazomib) capsules is effective in extending progression free survival (PFS) with a manageable tolerability profile in patients with relapsed and/or refractory multiple myeloma.

8 Dec 2015

Synthetic Biologics announces positive results from first SYN-004 Phase 2a study for prevention of CDI, AAD

Synthetic Biologics, Inc.), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen specific diseases, announced positive topline results from the first Phase 2a study of SYN-004, the Company's candidate designed to protect the gut microbiome from the unintended effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD).

1 Dec 2015

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications.

30 Nov 2015

Specific HRQOL components need to be targeted for achieving optimal care for older cancer patients

In a paper recently published in the European Journal of Cancer, EORTC researchers identified health related quality of life (HRQOL) components that should be considered as most relevant for achieving optimal care for older cancer patients.

26 Nov 2015

Slower aging reduces degeneration related to Parkinson's disease

Humans have long sought to reduce the effects of aging. Now, there may be another reason to continue searching for ways to slow the clock--preventing Parkinson's disease.

25 Nov 2015

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy.

23 Nov 2015

AfBPM's second National Summit aims to improve pain management, patient safety

The Alliance for Balanced Pain Management, a diverse collective of 24 health care advocacy groups, patient organizations, industry representatives and other stakeholders, held its second National Summit on Nov. 12 and 13, 2015, to identify continued ways to support appropriate access to integrated pain management and responsible use of prescription pain medicines with an aim to improve patient safety and reduce abuse.

21 Nov 2015

Ninlaro (ixazomib) approved to treat people with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy.

21 Nov 2015

Medical researchers use social media to study harmful side effects of narcotics medication

Harnessing the power of social media, medical researchers have sifted through more than two billion tweets and online posts to study the harmful side effects of narcotics medication taken for chronic pain.

19 Nov 2015

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).

19 Nov 2015

FDA approves Endo’s BELBUCA (buprenorphine) buccal film for use in patients with chronic pain

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, and BioDelivery Sciences International, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved BELBUCA (buprenorphine) buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

28 Oct 2015

Drug that relieves opioid-induced constipation may help some cancer patients live longer

Patients with advanced cancers who took a drug designed to relieve constipation caused by pain killers lived longer and had fewer reports of tumor progression than cancer patients who did not receive the drug, according to results presented October 27 at the 2015 meeting of the American Society of Anesthesiologists in San Diego. This is the first study in humans to associate opioid blockade with improved survival.

28 Oct 2015

Oxytocin treatment improves social, emotional and behavioral problems among young kids with autism

A five week treatment with the synthetic hormone oxytocin significantly improved social, emotional and behavioral issues among young children with autism, according to University of Sydney research published today in Molecular Psychiatry.

27 Oct 2015

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic).

24 Oct 2015

Veltassa (patiromer for oral suspension) gets FDA approval for treatment of hyperkalemia

The U.S. Food and Drug Administration today approved Veltassa (patiromer for oral suspension) to treat hyperkalemia, a serious condition in which the amount of potassium in the blood is too high.

22 Oct 2015

FDA grants accelerated approval to Praxbind (idarucizumab)

The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa's blood-thinning effects.

19 Oct 2015

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration granted approval of Praxbind (idarucizumab). PRAXBIND is indicated for patients treated with Pradaxa (dabigatran etexilate mesylate), when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.

16 Oct 2015

Loyola gastroenterologist provides tips to IBS patients for healthy living

More than 20 percent of the US population lives with irritable bowel syndrome (IBS) and for many Americans it is an ongoing challenge. But when it comes to treatment, old advice from Mom was right. Often, the key is to eat right and go outside and play.

16 Oct 2015

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

BioDelivery Sciences International, Inc. announced that the U.S. Food and Drug Administration has approved the company's Supplemental New Drug Application (sNDA) for a manufacturing specification change for BUNAVAIL (buprenorphine and naloxone) buccal film (CIII).

15 Oct 2015

Constipation News and Research

Latest Constipation News and Research

Kanuma approved as first treatment for patients with LAL deficiency

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Synthetic Biologics announces positive results from first SYN-004 Phase 2a study for prevention of CDI, AAD

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

Specific HRQOL components need to be targeted for achieving optimal care for older cancer patients

Slower aging reduces degeneration related to Parkinson's disease

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

AfBPM's second National Summit aims to improve pain management, patient safety

Ninlaro (ixazomib) approved to treat people with multiple myeloma

Medical researchers use social media to study harmful side effects of narcotics medication

Lilly, Merck expand oncology clinical trial collaboration

FDA approves Endo’s BELBUCA (buprenorphine) buccal film for use in patients with chronic pain

Drug that relieves opioid-induced constipation may help some cancer patients live longer

Oxytocin treatment improves social, emotional and behavioral problems among young kids with autism

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

Veltassa (patiromer for oral suspension) gets FDA approval for treatment of hyperkalemia

FDA grants accelerated approval to Praxbind (idarucizumab)

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Loyola gastroenterologist provides tips to IBS patients for healthy living

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Constipation News and Research

Latest Constipation News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in